<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>148534</routedMedId>
		<routedMedName>Letairis oral</routedMedName>
		<routedGenericName>ambrisentan oral</routedGenericName>
		<etcIds>
			<etc_id>4549</etc_id>
		</etcIds>
		<medIds>
			<medId>551403</medId>
			<medId>551402</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Pulmonary Hypertensive Arterial Disease</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.13784</icd9>
			<symbolic>Letairis-PAH</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype_name>
				<name></name>
			</subtype_name>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name></subtype_name>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
		  <concurrentTherapyExclusion>
		    <criteriaSet>  
		      <excludedTherapy>
		        <treatment>  
		          <treatmentLine> 
		            <option>WITH</option>
		            <interventionType>drug</interventionType>
		            <name/>
		            <codeValues/>
		            <selectedListName/>
		            <selectedListClassCode/>
		          </treatmentLine>
		        </treatment>
		      </excludedTherapy>
		    </criteriaSet>
		  </concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Letairis (ambrisentan) tablets, for oral use. Physician Prescribing Information [Internet] Gilead Sciences, Inc. 2013 Aug Accessed at: http://www.letairis.com/. [created 2007; accessed 2013 Dec 2]</reference>
				<reference>Buckley MS, et al. Pharmacokinetic evaluation of ambrisentan. Expert Opinion on Drug Metabolism &amp; Toxicology 2011;7(3):371-80. DOI: 10.1517/17425255.2011.557181.</reference>
				<reference>Frampton JE. Ambrisentan. American Journal of Cardiovascular Drugs 2011;11(4):215-26. DOI: 10.2165/11207340-000000000-00000.</reference>
				<reference>Anderson JR, Nawarskas JJ. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiology in Review 2010;18(3):148-62. DOI: 10.1097/CRD.0b013e3181d4e921.</reference>
				<reference>McLaughlin VV, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Journal of the American College of Cardiology 2009;53(17):1573-619. DOI: 10.1016/j.jacc.2009.01.004. (Reaffirmed 2013 Nov)</reference>
				<reference>Walker G, Mandagere A, Dufton C, Venitz J. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. British Journal of Clinical Pharmacology 2009;67(5):527-34. DOI: 10.1111/j.1365-2125.2009.03384.x.</reference>
				<reference>Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal 2009;30(20):2493-537. DOI: 10.1093/eurheartj/ehp297. (Reaffirmed 2013 Nov)</reference>
				<reference>Barst RJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology 2009;54(1 Suppl):S78-84. DOI: 10.1016/j.jacc.2009.04.017.</reference>
				<reference>Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD004434. DOI: 10.1002/14651858.CD004434.pub5.</reference>
				<reference>Galie N, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-9. DOI: 10.1161/CIRCULATIONAHA.107.742510.</reference>
				<reference>Oudiz RJ, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. Journal of the American College of Cardiology 2009;54(21):1971-81. DOI: 10.1016/j.jacc.2009.07.033.</reference>
				<reference>Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. American Journal of Cardiology 2011;108(2):302-7. DOI: 10.1016/j.amjcard.2011.03.037.</reference>
				<reference>Blalock SE, et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. Journal of Cardiac Failure 2010;16(2):121-7. DOI: 10.1016/j.cardfail.2009.09.008.</reference>
				<reference>Ryerson CJ, Nayar S, Swiston JR, Sin DD. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respiratory Research 2010;11:12. DOI: 10.1186/1465-9921-11-12.</reference>
				<reference>Simonneau G, et al. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 2009;54(1 Suppl):S43-54. DOI: 10.1016/j.jacc.2009.04.012.</reference>
				<reference>Baumgartner H, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). European Heart Journal 2010;31(23):2915-57. DOI: 10.1093/eurheartj/ehq249.</reference>
				<reference>Gupta V, Tonelli AR, Krasuski RA. Congenital heart disease and pulmonary hypertension. Heart Failure Clinics 2012;8(3):427-45. DOI: 10.1016/j.hfc.2012.04.002.</reference>
				<reference>Nakanishi N, European Society of Cardiology, European Respiratory Society. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. Allergology International 2011;60(4):419-24. DOI: 10.2332/allergolint.11-RAI-0362. (Reaffirmed 2013 Nov)</reference>
				<reference>Walker KM, Pope J, participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. Seminars in Arthritis and Rheumatism 2012;42(1):42-55. DOI: 10.1016/j.semarthrit.2012.01.003.</reference>
				<reference>Grunig E. Treatment of pulmonary arterial hypertension in connective tissue disease. Drugs 2012;72(8):1039-56. DOI: 10.2165/11633390-000000000-00000.</reference>
				<reference>McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology 2009;48 Suppl 3:iii25-31. DOI: 10.1093/rheumatology/kep107.</reference>
				<reference>Janda S, Quon BS, Swiston J. HIV and pulmonary arterial hypertension: a systematic review. HIV Medicine 2010;11(10):620-34. DOI: 10.1111/j.1468-1293.2010.00829.x.</reference>
				<reference>Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: an update. Liver Transplantation 2012;18(8):881-91. DOI: 10.1002/lt.23485.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Pulmonary Arterial Hypertension due to Chronic Obstructive or Interstitial Lung Disease-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Badesch DB, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovascular Therapeutics 2012;30(2):93-9. DOI: 10.1111/j.1755-5922.2011.00279.x.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Pulmonary Arterial Hypertension due to Sickle Cell Disease-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT, Kato GJ. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. British Journal of Haematology 2009;147(5):737-43. DOI: 10.1111/j.1365-2141.2009.07906.x.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
	</lists>
</paload>
